Moderna coronavirus vaccine nearly 95% effective in early analysis

Published



Pharmaceutical company Moderna announced that its lead vaccine candidate is nearly 95% effective based on an early analysis from an independent board.

“This is a pivotal moment in the development of our COVID-19 vaccine candidate,” Moderna CEO Stephane Bancel said on Monday. “This milestone is only possible because of the hard work and sacrifices of so many.”

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.